2017 to 2022 Saw More Than Doubling in Use of GLP-1 Receptor Agonists

MONDAY, July 20, 2026-- From 2017 to 2022, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) more than doubled, according to a study published online July 17 in the Journal of the American Heart Association.Michael M. Hammond, M.D...